causal
Harms often emerge only in large Phase 3 trials
Drugs that reach Phase 3 randomized clinical trials have passed substantial vetting for safety and efficacy signals, yet larger trials with broader patient populations often reveal that the therapy is far less effective than thought or carries previously unrecognized adverse effects, and developers invested for years face a strong temptation to dismiss negative data and push through.
causalpending
Speaker
Adam CifuEvidence Quote
“there's a temptation to say, 'Ach, that data is wrong. Let's push through.' Added to it that there is a lot of money involved here.”
Created: 6/13/2026, 12:18:13 AM
Your notes
Loading notes...